Upstream Bio Presents New Structural Data on Verekitug, Highlights Unique TSLP Receptor Targeting [Yahoo! Finance]
Upstream Bio, Inc. (UPB)
Company Research
Source: Yahoo! Finance
and mechanistic data for its therapeutic candidate, verekitug, at the European Respiratory Society/ERS Congress. The congress was held from September 27 – October 1 in Amsterdam, Netherlands. The data, presented on September 30, elucidated the drivers of verekitug's potent pharmacodynamic activity and its unique mechanism of targeting the thymic stromal lymphopoietin/TSLP receptor. Verekitug is a novel recombinant fully human immunoglobulin G1 (IgG1) monoclonal antibody and the only known monoclonal antibody currently in clinical development that targets and inhibits the TSLP receptor. The structural and mechanistic findings support a differentiated therapeutic effect by showing that verekitug binds to the TSLP receptor with high affinity. The high-resolution crystal structure reveals that verekitug effectively occupies most of the TSLP binding sites on the TSLP receptor, which prevents TSLP from binding. Upstream Bio Presents New Structural Data on Verekitug, Highlights Unique TS
Show less
Read more
Impact Snapshot
Event Time:
UPB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
UPB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
UPB alerts
High impacting Upstream Bio, Inc. news events
Weekly update
A roundup of the hottest topics
UPB
News
- Upstream Bio (NASDAQ:UPB) is now covered by analysts at Lifesci Capital. They set an "outperform" rating and a $43.00 price target on the stock.MarketBeat
- Upstream Bio (UPB): Evaluating Valuation After 10% Share Price Surge [Yahoo! Finance]Yahoo! Finance
- Upstream Bio to Participate in Upcoming December Investor Conferences [Yahoo! Finance]Yahoo! Finance
- Upstream Bio to Participate in Upcoming December Investor ConferencesGlobeNewswire
- Upstream Bio Reports Third Quarter 2025 Financial Results and Highlights Continued ProgressGlobeNewswire
UPB
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- 11/5/25 - Form S-3ASR
- UPB's page on the SEC website